|
1
|
Hanahan D and Weinberg R: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg R: The hallmarks of
cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Green G, Carmona R, Zakeri K, Lee CH,
Borgan S, Marhoon Z, Sharabi A and Mell LK: Specificity of genetic
biomarker studies in cancer research: A systematic review. PLoS
One. 11:e01564892016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhagwat AS and Vakoc CR: Targeting
transcription factors in cancer. Trends Cancer. 1:53–65. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yeh JE, Toniolo PA and Frank DA: Targeting
transcription factors: Promising new strategies for cancer therapy.
Curr Opin Oncol. 25:652–658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Darnell JE: Transcription factors as
targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chuang LS, Ito K and Ito Y: RUNX family:
Regulation and diversification of roles through interacting
proteins. Int J Cancer. 132:1260–1271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blyth K, Cameron ER and Neil JC: The RUNX
genes: Gain or loss of function in cancer. Nat Rev Cancer.
5:376–387. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dowdy CR, Xie R, Frederick D, Hussain S,
Zaidi SK, Vradii D, Javed A, Li X, Jones SN, Lian JB, et al:
Definitive hematopoiesis requires Runx1 C-terminal-mediated
subnuclear targeting and transactivation. Hum Mol Genet.
19:1048–1057. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamagata T, Maki K and Mitani K:
Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol.
82:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lian JB, Javed A, Zaidi SK, Lengner C,
Montecino M, van Wijnen AJ, Stein JL and Stein GS: Regulatory
controls for osteoblast growth and differentiation: Role of
Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr. 14:1–41. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lian JB and Stein GS: Runx2/Cbfa1: A
multifunctional regulator of bone formation. Curr Pharm Des.
9:2677–2685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Komori T: Requisite roles of Runx2 and
Cbfb in skeletal development. J Bone Miner Metab. 21:193–197.
2003.PubMed/NCBI
|
|
15
|
Fukamachi H: Runx3 controls growth and
differentiation of gastric epithelial cells in mammals. Dev Growth
Differ. 48:1–13. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Osato M: Point mutations in the RUNX1/AML1
gene: Another actor in RUNX leukemia. Oncogene. 23:4284–4296. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
De Braekeleer E, Férec C and De Braekeleer
M: RUNX1 translocations in malignant hemopathies. Anticancer Res.
29:1031–1037. 2009.PubMed/NCBI
|
|
18
|
Niini T, Kanerva J, Vettenranta K,
Saarinen-Pihkala UM and Knuutila S: AML1 gene amplification: A
novel finding in childhood acute lymphoblastic leukemia.
Haematologica. 85:362–366. 2000.PubMed/NCBI
|
|
19
|
Chuang LS and Ito Y: RUNX3 is
multifunctional in carcinogenesis of multiple solid tumors.
Oncogene. 29:2605–2615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taniuchi I, Osato M and Ito Y: Runx1: No
longer just for leukemia. EMBO J. 31:4098–4099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sadikovic B, Thorner P, Chilton-MacNeill
S, Martin JW, Cervigne NK, Squire J and Zielenska M: Expression
analysis of genes associated with human osteosarcoma tumors shows
correlation of RUNX2 overexpression with poor response to
chemotherapy. BMC Cancer. 10:2022010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kurek KC, Del Mare S, Salah Z, Abdeen S,
Sadiq H, Lee SH, Gaudio E, Zanesi N, Jones KB, DeYoung B, et al:
Frequent attenuation of the WWOX tumor suppressor in osteosarcoma
is associated with increased tumorigenicity and aberrant RUNX2
expression. Cancer Res. 70:5577–5586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lau CC, Harris CP, Lu XY, Perlaky L,
Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos
AG, et al: Frequent amplification and rearrangement of chromosomal
bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes
Cancer. 39:11–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Endo T, Ohta K and Kobayashi T: Expression
and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells.
J Clin Endocrinol Metab. 93:2409–2412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dalle Carbonare L, Frigo A, Francia G,
Davì MV, Donatelli L, Stranieri C, Brazzarola P, Zatelli MC,
Menestrina F and Valenti MT: Runx2 mRNA expression in the tissue,
serum, and circulating non-hematopoietic cells of patients with
thyroid cancer. J Clin Endocrinol Metab. 97:E1249–E1256. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barnes GL, Javed A, Waller SM, Kamal MH,
Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian
JB, et al: Osteoblast-related transcription factors Runx2
(Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein
in human metastatic breast cancer cells. Cancer Res. 63:2631–2637.
2003.PubMed/NCBI
|
|
27
|
Barnes GL, Hebert KE, Kamal M, Javed A,
Einhorn TA, Lian JB, Stein GS and Gerstenfeld LC: Fidelity of Runx2
activity in breast cancer cells is required for the generation of
metastases-associated osteolytic disease. Cancer Res. 64:4506–4513.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leong DT, Lim J, Goh X, Pratap J, Pereira
BP, Kwok HS, Nathan SS, Dobson JR, Lian JB, Ito Y, et al:
Cancer-related ectopic expression of the bone-related transcription
factor RUNX2 in non-osseous metastatic tumor cells is linked to
cell proliferation and motility. Breast Cancer Res. 12:R892010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Friedrich MJ, Rad R, Langer R, Voland P,
Hoefler H, Schmid RM, Prinz C and Gerhard M: Lack of RUNX3
regulation in human gastric cancer. J Pathol. 210:141–146. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kilbey A, Terry A, Cameron ER and Neil JC:
Oncogene-induced senescence: An essential role for Runx. Cell
Cycle. 7:2333–2340. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blyth K, Vaillant F, Jenkins A, McDonald
L, Pringle MA, Huser C, Stein T, Neil J and Cameron ER: Runx2 in
normal tissues and cancer cells: A developing story. Blood Cells
Mol Dis. 45:117–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cameron ER and Neil JC: The Runx genes:
Lineage-specific oncogenes and tumor suppressors. Oncogene.
23:4308–4314. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Coffman JA: Runx transcription factors and
the developmental balance between cell proliferation and
differentiation. Cell Biol Int. 27:315–324. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sullivan JC, Sher D, Eisenstein M,
Shigesada K, Reitzel AM, Marlow H, Levanon D, Groner Y, Finnerty JR
and Gat U: The evolutionary origin of the Runx/CBFbeta
transcription factors-studies of the most basal metazoans. BMC Evol
Biol. 8:2282008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nam S, Jin YH, Li QL, Lee KY, Jeong GB,
Ito Y, Lee J and Bae SC: Expression pattern, regulation, and
biological role of runt domain transcription factor, run, in
Caenorhabditis elegans. Mol Cell Biol. 22:547–554. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rennert J, Coffman JA, Mushegian AR and
Robertson AJ: The evolution of Runx genes I. A comparative study of
sequences from phylogenetically diverse model organisms. BMC Evol
Biol. 3:42003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Robertson AJ, Dickey-Sims C, Ransick A,
Rupp DE, McCarthy JJ and Coffman JA: CBFbeta is a facultative Runx
partner in the sea urchin embryo. BMC Biol. 4:42006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Warren AJ, Bravo J, Warren AJ and Rabbitts
TH: Structural basis for the heterodimeric interaction between the
acute leukaemia-associated transcription factors AML1 and CBFβ.
EMBO J. 19:3004–3015. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ito Y, Bae SC and Chuang LS: The RUNX
family: Developmental regulators in cancer. Nat Rev Cancer.
15:81–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Levanon D, Negreanu V, Bernstein Y, Bar-Am
I, Avivi L and Groner Y: AML1, AML2, and AML3, the human members of
the runt domain gene-family: CDNA structure, expression, and
chromosomal localization. Genomics. 23:425–432. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bae SC, Takahashi E, Zhang YW, Ogawa E,
Shigesada K, Namba Y, Satake M and Ito Y: Cloning, mapping and
expression of PEBP2 alpha C, a third gene encoding the mammalian
Runt domain. Gene. 159:245–248. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Levanon D and Groner Y: Structure and
regulated expression of mammalian RUNX genes. Oncogene.
23:4211–4219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bangsow C, Rubins N, Glusman G, Bernstein
Y, Negreanu V, Goldenberg D, Lotem J, Ben-Asher E, Lancet D,
Levanon D and Groner Y: The RUNX3 gene-sequence, structure and
regulated expression. Gene. 279:221–232. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Marshall LJ, Moore AC, Ohki M, Kitabayashi
I, Patterson D and Ornelles DA: RUNX1 permits E4orf6-directed
nuclear localization of the adenovirus E1B-55K protein and
associates with centers of viral DNA and RNA synthesis. J Virol.
82:6395–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stock M and Otto F: Control of RUNX2
isoform expression: The role of promoters and enhancers. J Cell
Biochem. 95:506–517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miyoshi H, Ohira M, Shimizu K, Mitani K,
Hirai H, Imai T, Yokoyama K, Soeda E and Ohki M: Alternative
splicing and genomic structure of the AML1 gene involved in acute
myeloid leukemia. Nucleic Acids Res. 23:2762–2769. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kagoshima H, Shigesada K, Satake M, Ito Y,
Miyoshi H, Ohki M, Pepling M and Gergen P: The runt domain
identifies a new family of heterometric transcriptional regulators.
Trends Genet. 9:338–341. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nagata T, Gupta V, Sorce D, Kim WY, Sali
A, Chait BT, Shigesada K, Ito Y and Werner MH: Immunoglobulin motif
DNA recognition and heterodimerization of the PEBP2/CBF Runt
domain. Nat Struct Biol. 6:615–619. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Williams AF and Barclay AN: The
immunoglobulin superfamily-domains for cell surface recognition.
Annu Rev Immunol. 6:381–405. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Javed A, Guo B, Hiebert S, Choi JY, Green
J, Zhao SC, Osborne MA, Stifani S, Stein JL, Lian JB, et al:
Groucho/TLE/R-esp proteins associate with the nuclear matrix and
repress RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of
tissue-specific gene transcription. J Cell Sci. 113:2221–2231.
2000.PubMed/NCBI
|
|
51
|
Imai Y, Kurokawa M, Tanaka K, Friedman AD,
Ogawa S, Mitani K, Yazaki Y and Hirai H: TLE, the human homolog of
groucho, interacts with AML1 and acts as a repressor of
AML1-induced transactivation. Biochem Biophys Res Commun.
252:582–589. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zaidi SK, Javed A, Choi JY, van Wijnen AJ,
Stein JL, Lian JB and Stein GS: A specific targeting signal directs
Runx2/Cbfa1 to subnuclear domains and contributes to
transactivation of the osteocalcin gene. J Cell Sci. 114:3093–3102.
2001.PubMed/NCBI
|
|
53
|
Stein GS, Lian JB, Stein JL, van Wijnen
AJ, Choi JY, Pratap J and Zaidi SK: Temporal and spatial parameters
of skeletal gene expression: Targeting RUNX factors and their
coregulatory proteins to subnuclear domains. Connect Tissue Res. 44
(Suppl 1):S149–S153. 2003. View Article : Google Scholar
|
|
54
|
Harrington KS, Javed A, Drissi H, McNeil
S, Lian JB, Stein JL, Van Wijnen AJ, Wang YL and Stein GS:
Transcription factors RUNX1/AML1 and RUNX2/Cbfa1 dynamically
associate with stationary subnuclear domains. J Cell Sci.
115:4167–4176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kanno T, Takahashi T, Tsujisawa T,
Ariyoshi W and Nishihara T: Mechanical stress-mediated Runx2
activation is dependent on Ras/ERK1/2 MAPK signaling in
osteoblasts. J Cell Biochem. 101:1266–1277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Terry A, Kilbey A, Vaillant F, Stewart M,
Jenkins A, Cameron E and Neil JC: Conservation and expression of an
alternative 3′exon of Runx2 encoding a novel proline-rich
C-terminal domain. Gene. 336:115–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tahirov TH, Inoue-Bungo T, Morii H,
Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T,
Yamamoto M, et al: Structural analyses of DNA recognition by the
AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.
Cell. 104:755–767. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pozner A, Goldenberg D, Negreanu V, Le S,
Elroy-stein O, Levanon D and Groner Y: Transcription-coupled
translation control of AML1/RUNX1 is mediated by Cap-and internal
ribosome entry site-dependent mechanisms. Mol Cell Biol.
20:2297–2307. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xiao ZS, Simpson LG and Quarles LD:
IRES-dependent translational control of Cbfa1/Runx2 expression. J
Cell Biochem. 88:493–505. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tang X, Sun L, Wang G, Chen B and Luo F:
RUNX1: A regulator of NF-kB signaling in pulmonary diseases. Curr
Protein Pept Sci. 19:172–178. 2018.PubMed/NCBI
|
|
61
|
Webber BR, Iacovino M, Choi SH, Tolar J,
Kyba M and Blazar BR: DNA methylation of Runx1 regulatory regions
correlates with transition from primitive to definitive
hematopoietic potential in vitro and in vivo. Blood. 122:2978–2986.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sood R, Kamikubo Y and Liu P: Role of
RUNX1 in hematological malignancies. Blood. 129:2070–2082. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jonason JH, Xiao G, Zhang M, Xing L and
Chen D: Post-translational Regulation of Runx2 in Bone and
Cartilage. J Dent Res. 88:693–703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Rojas A, Aguilar R, Henriquez B, Lian JB,
Stein JL, Stein GS, van Wijnen AJ, van Zundert B, Allende ML and
Montecino M: Epigenetic control of the bone-master Runx2 gene
during osteoblast-lineage commitment by the histone demethylase
JARID1B/KDM5B. J Biol Chem. 290:28329–28342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
O'Riordan M and Grosschedl R:
Transcriptional regulation of early B-lymphocyte differentiation.
Immunol Rev. 175:94–103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Leiden JM and Thompson CB: Transcriptional
regulation of T-cell genes during T-cell development. Curr Opin
Immunol. 6:231–237. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kurklu B, Whitehead RH, Ong EK, Minamoto
T, Fox JG, Mann JR, Judd LM, Giraud AS and Menheniott TR:
Lineage-specific RUNX3 hypomethylation marks the preneoplastic
immune component of gastric cancer. Oncogene. 34:2856–2866. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Appel E, Weissmann S, Salzberg Y, Orlovsky
K, Negreanu V, Tsoory M, Raanan C, Feldmesser E, Bernstein Y,
Wolstein O, et al: An ensemble of regulatory elements controls
Runx3 spatiotemporal expression in subsets of dorsal root ganglia
proprioceptive neurons. Genes Dev. 30:2607–2622. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Levanon D, Lotem J, Negreanu V, et al:
Transcription regulation in development and disease. Life Sci Open
Day. 1–3. 2008.
|
|
70
|
Kojo S, Tanaka H, Endo TA, Muroi S, Liu Y,
Seo W, Tenno M, Kakugawa K, Naoe Y, Nair K, et al: Priming of
lineage-specifying genes by Bcl11b is required for lineage choice
in post-selection thymocytes. Nat Commun. 8:7022017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cho JY, Akbarali Y, Zerbini LF, Gu X,
Boltax J, Wang Y, Oettgen P, Zhang DE and Libermann TA: Isoforms of
the Ets transcription factor NERF/ELF-2 physically interact with
AML1 and mediate opposing effects on AML1-mediated transcription of
the B cell-specific blk gene. J Biol Chem. 279:19512–19522. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
D'Alonzo RC, Selvamurugan N, Karsenty G
and Partridge NC: Physical interaction of the activator protein-1
factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter
activation. J Biol Chem. 277:816–822. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Pelletier N, Champagne N, Stifani S and
Yang XJ: MOZ and MORF histone acetyltransferases interact with the
Runt-domain transcription factor Runx2. Oncogene. 21:2729–2740.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Levanon D, Glusman G, Bangsow T, Ben-Asher
E, Male DA, Avidan N, Bangsow C, Hattori M, Taylor TD, Taudien S,
et al: Architecture and anatomy of the genomic locus encoding the
human leukemia-associated transcription factor RUNX1/AML1. Gene.
262:23–33. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Aho TL, Sandholm J, Peltola KJ, Ito Y and
Koskinen PJ: Pim-1 kinase phosphorylates RUNX family transcription
factors and enhances their activity. BMC Cell Biol. 7:212006.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kim HR, Oh BC, Choi JK and Bae SC: Pim-1
kinase phosphorylates and stabilizes RUNX3 and alters its
subcellular localization. J Cell Biochem. 105:1048–1058. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Blyth K, Terry A, Mackay N, Vaillant F,
Bell M, Cameron ER, Neil JC and Stewart M: Runx2: A novel oncogenic
effector revealed by in vivo complementation and retroviral
tagging. Oncogene. 20:295–302. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tanaka T, Kurokawa M, Ueki K, Tanaka K,
Imai Y, Mitani K, Okazaki K, Sagata N, Yazaki Y, Shibata Y, et al:
The extracellular signal-regulated kinase pathway phosphorylates
AML1, an acute myeloid leukemia gene product, and potentially
regulates its transactivation ability. Mol Cell Biol. 16:3967–3979.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Imai Y, Kurokawa M, Yamaguchi Y, Izutsu K,
Nitta E, Mitani K, Satake M, Noda T, Ito Y and Hirai H: The
corepressor mSin3A regulates phosphorylation-induced activation,
intranuclear location, and stability of AML1. Mol Cell Biol.
24:1033–1043. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wee HJ, Voon DC, Bae SC and Ito Y:
PEBP2-beta/CBF-beta dependent phosphorylation of RUNX1 and p300 by
HIPK2: Implications for leukemogenesis. Blood. 112:3777–3787. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Aikawa Y, Nguyen LA, Isono K, Takakura N,
Tagata Y, Schmitz ML, Koseki H and Kitabayashi I: Roles of HIPK1
and HIPK2 in AML1-and p300-dependent transcription, hematopoiesis
and blood vessel formation. EMBO J. 25:3955–3965. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Seo W, Tanaka H, Miyamoto C, Levanon D,
Groner Y and Taniuchi I: Roles of VWRPY motif-mediated gene
repression by Runx proteins during T-cell development. Immunol Cell
Biol. 90:827–830. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Westendorf JJ, Zaidi SK, Cascino JE,
Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS and Li X:
Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and
represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 22:7982–7992.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Durst KL and Hiebert SW: Role of RUNX
family members in transcriptional repression and gene silencing.
Oncogene. 23:4220–4224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Kasahara K, Shiina M, Fukuda I, Ogata K
and Nakamura H: Molecular mechanisms of cooperative binding of
transcription factors Runx1-CBFβ-Ets1 on the TCRα gene enhancer.
PLoS One. 12:e01726542017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hassig CA, Fleischer TC, Billin AN,
Schreiber SL and Ayer DE: Histone deacetylase activity is required
for full transcriptional repression by mSin3A. Cell. 89:341–347.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Gelmetti V, Zhang J, Fanelli M, Minucci S,
Pelicci PG and Lazar MA: Aberrant recruitment of the nuclear
receptor corepressor-histone deacetylase complex by the acute
myeloid leukemia fusion partner ETO. Mol Cell Biol. 18:7185–7191.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Huang G, Shigesada K, Ito K, Wee HJ,
Yokomizo T and Ito Y: Dimerization with PEBP2beta protects
RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J.
20:723–733. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zelent A, Greaves M and Enver T: Role of
the TEL-AML1 fusion gene in the molecular pathogenesis of childhood
acute lymphoblastic leukaemia. Oncogene. 23:4275–4283. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Bakshi R, Hassan MQ, Pratap J, Lian JB,
Montecino MA, van Wijnen AJ, Stein JL, Imbalzano AN and Stein GS:
The human SWI/SNF complex associates with RUNX1 to control
transcription of hematopoietic target genes. J Cell Physiol.
225:569–576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Henriquez B, Hepp M, Merino P, Sepulveda
H, van Wijnen AJ, Lian JB, Stein GS, Stein JL and Montecino M:
C/EBPβ binds the P1 promoter of the Runx2 gene and up-regulates
Runx2 transcription in osteoblastic cells. J Cell Physiol.
226:3043–3052. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
De Bruijn M and Dzierzak E: Runx
transcription factors in the development and function of the
definitive hematopoietic system. Blood. 129:2061–2069. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Inoue K, Ozaki S, Shiga T, Ito K, Masuda
T, Okado N, Iseda T, Kawaguchi S, Ogawa M, Bae SC, et al: Runx3
controls the axonal projection of proprioceptive dorsal root
ganglion neurons. Nat Neurosci. 5:946–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Senzaki K, Ozaki S, Yoshikawa M, Ito Y and
Shiga T: Runx3 is required for the specification of TrkC-expressing
mechanoreceptive trigeminal ganglion neurons. Mol Cell Neurosci.
43:296–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Woolf E, Brenner O, Goldenberg D, Levanon
D and Groner Y: Runx3 regulates dendritic epidermal T cell
development. Dev Biol. 303:703–714. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kamikubo Y: Genetic compensation of RUNX
family transcription factors in leukemia. Cancer Sci.
109:2358–2363. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ross K, Sedello AK, Todd GP,
Paszkowski-Rogacz M, Bird AW, Ding L, Grinenko T, Behrens K, Hubner
N, Mann M, et al: Polycomb group ring finger 1 cooperates with
Runx1 in regulating differentiation and self-renewal of
hematopoietic cells. Blood. 119:4152–4161. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yokomizo T, Ogawa M, Osato M, Kanno T,
Yoshida H, Fujimoto T, Fraser S, Nishikawa S, Okada H, Satake M, et
al: Requirement of Runx1/AML1/PEBP2alphaB for the generation of
haematopoietic cells from endothelial cells. Genes Cells. 6:13–23.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Tanaka K, Tanaka T, Ogawa S, Kurokawa M,
Mitani K, Yazaki Y and Hirai H: Increased expression of AML1 during
retinoic-acid-induced differentiation of U937 cells. Biochem
Biophys Res Commun. 211:1023–1030. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Pratap J, Galindo M, Zaidi SK, Vradii D,
Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, et al:
Cell growth regulatory role of Runx2 during proliferative expansion
of preosteoblasts. Cancer Res. 63:5357–5362. 2003.PubMed/NCBI
|
|
101
|
Galindo M, Pratap J, Young DW,
Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS and van
Wijnen AJ: The bone-specific expression of Runx2 oscillates during
the cell cycle to support a G 1-related Antiproliferative function
in osteoblasts. J Biol Chem. 280:20274–20285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Stein GS, Lian JB, Van Wijnen AJ, Stein
JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY and Pockwinse
SM: Runx2 control of organization, assembly and activity of the
regulatory machinery for skeletal gene expression. Oncogene.
23:4315–4329. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Krege JH, Hodgin JB, Couse JF, Enmark E,
Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA and Smithies
O: Generation and reproductive phenotypes of mice lacking estrogen
receptor beta. Proc Natl Acad Sci USA. 95:15677–15682. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ehrhardt GR, Hijikata A, Kitamura H, Ohara
O, Wang JY and Cooper MD: Discriminating gene expression profiles
of memory B cell subpopulations. J Exp Med. 205:1807–1817. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Vaillant F, Blyth K, Andrew L, Neil JC and
Cameron ER: Enforced expression of Runx2 perturbs T cell
development at a stage coincident with beta-selection. J Immunol.
169:2866–2874. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Taniuchi I, Osato M, Egawa T, Sunshine MJ,
Bae SC, Komori T, Ito Y and Littman DR: Differential requirements
for Runx proteins in CD4 repression and epigenetic silencing during
T lymphocyte development. Cell. 111:621–633. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bauer O, Sharir A, Kimura A, Hantisteanu
S, Takeda S and Groner Y: Loss of osteoblast Runx3 produces severe
congenital osteopenia. Mol Cell Biol. 35:1097–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wotton S, Terry A, Kilbey A, Jenkins A,
Herzyk P and Neil JC: UKPMC funders group gene array analysis
reveals a common Runx transcriptional program controlling cell
adhesion and survival. Oncogene. 27:5856–5866. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zaidi SK, Pande S, Pratap J, Gaur T,
Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ and Stein GS:
Runx2 deficiency and defective subnuclear targeting bypass
senescence to promote immortalization and tumorigenic potential.
Proc Natl Acad Sci USA. 104:19861–19866. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ghali O, Chauveau C, Hardouin P, Broux O
and Devedjian JC: TNF-alpha's effects on proliferation and
apoptosis in human mesenchymal stem cells depend on RUNX2
expression. J Bone Miner Res. 25:1616–1626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Scheitz CJ, Lee TS, McDermitt DJ and
Tumbar T: Defining a tissue stem cell-driven Runx1/Stat3 signalling
axis in epithelial cancer. EMBO J. 31:4124–4139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Speck NA and Gilliland DG: Core-binding
factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2:502–513.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
113
|
Look AT: Oncogenic transcription factors
in the human acute leukemias. Science. 278:1059–1064. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Regha K, Assi SA, Tsoulaki O, Gilmour J,
Lacaud G and Bonifer C: Developmental-stage-dependent
transcriptional response to leukaemic oncogene expression. Nat
Commun. 6:72032015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Golub TR, Barker GF, Bohlander SK, Hiebert
SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD and
Gilliland DG: Fusion of the TEL gene on 12p13 to the AML1 gene on
21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA.
92:4917–4921. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Nucifora G and Rowley JD: AMLl and the
8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
Blood. 86:1–14. 1995.PubMed/NCBI
|
|
117
|
Mitani K, Ogawa S, Tanaka T, Miyoshi H,
Kurokawa M, Mano H, Yazaki Y, Ohki M and Hirai H: Generation of the
AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic
crisis in chronic myelocytic leukemia. EMBO J. 13:504–510. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Krygier A, Szmajda D, Żebrowska M, Jeleń A
and Balcerczak E: Expression levels of the runt-related
transcription factor 1 and 3 genes in the development of acute
myeloid leukemia. Oncol Lett. 15:6733–6738. 2018.PubMed/NCBI
|
|
119
|
Wotton S, Stewart M, Blyth K, Vaillant F,
Kilbey A, Neil JC and Cameron ER: Proviral insertion indicates a
dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer
Res. 62:7181–7185. 2002.PubMed/NCBI
|
|
120
|
Osato M, Asou N, Abdalla E, Hoshino K,
Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K
and Ito Y: Biallelic and heterozygous point mutations in the runt
domain of the AML1/PEBP2alphaB gene associated with myeloblastic
leukemias. Blood. 93:1817–1824. 1999.PubMed/NCBI
|
|
121
|
Song WJ, Sullivan MG, Legare RD, Hutchings
S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, et
al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia
with propensity to develop acute myelogenous leukaemia. Nat Genet.
23:166–175. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
122
|
Fonatsch C: The role of chromosome 21 in
hematology and oncology. Genes Chromosomes Cancer. 49:497–508.
2010.PubMed/NCBI
|
|
123
|
Banerji S, Cibulskis K, Rangel-Escareno C,
Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY,
Sougnez C, Zou L, et al: Sequence analysis of mutations and
translocations across breast cancer subtypes. Nature. 486:405–409.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ,
Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al:
Whole-genome analysis informs breast cancer response to aromatase
inhibition. Nature. 486:353–360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Morita K, Suzuki K, Maeda S, Matsuo A,
Mitsuda Y, Tokushige C, Kashiwazaki G, Taniguchi J, Maeda R, Noura
M, et al: Genetic regulation of the RUNX transcription factor
family has antitumor effects. J Clin Invest. 127:2815–2828. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Illendula A, Gilmour J, Grembecka J,
Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan
JA, Zong H, et al: Small molecule inhibitor of CBFβ-RUNX binding
for RUNX transcription factor driven cancers. EBioMedicine.
8:117–131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Pelassa I, Corà D, Cesano F, Monje FJ,
Montarolo PG and Fiumara F: Association of polyalanine and
polyglutamine coiled coils mediates expansion disease-related
protein aggregation and dysfunction. Hum Mol Genet. 23:3402–3420.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Stewart M, Terry A, Hu M, O'Hara M, Blyth
K, Baxter E, Cameron E, Onions DE and Neil JC: Proviral insertions
induce the expression of bone-specific isoforms of PEBP2alphaA
(CBFA1): Evidence for a new myc collaborating oncogene. Proc Natl
Acad Sci USA. 94:8646–8651. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Martin JW, Zielenska M, Stein GS, Van
Wijnen AJ and Squire JA: The role of RUNX2 in osteosarcoma
oncogenesis. Sarcoma. 2011:2827452011. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Li N, Luo D, Hu X, Luo W, Lei G, Wang Q,
Zhu T, Gu J, Lu Y and Zheng Q: RUNX2 and Osteosarcoma. Anticancer
Agents Med Chem. 15:881–887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Pratap J, Lian JB, Javed A, Barnes GL, van
Wijnen AJ, Stein JL and Stein GS: Regulatory roles of Runx2 in
metastatic tumor and cancer cell interactions with bone. Cancer
Metastasis Rev. 25:589–600. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Rucci N and Teti A: Osteomimicry: How
tumor cells try to deceive the bone. Front Biosci (Schol Ed).
2:907–915. 2010.PubMed/NCBI
|
|
133
|
Niu DF, Kondo T, Nakazawa T, Oishi N,
Kawasaki T, Mochizuki K, Yamane T and Katoh R: Transcription factor
Runx2 is a regulator of epithelial-mesenchymal transition and
invasion in thyroid carcinomas. Lab Invest. 92:1181–1190. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Lim M, Zhong C, Yang S, Bell AM, Cohen MB
and Roy-Burman P: Runx2 regulates survivin expression in prostate
cancer cells. Lab Invest. 90:222–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Pratap J, Javed A, Languino LR, van Wijnen
AJ, Stein JL, Stein GS and Lian JB: The Runx2 osteogenic
transcription factor regulates matrix metalloproteinase 9 in bone
metastatic cancer cells and controls cell invasion. Mol Cell Biol.
25:8581–8591. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Onodera Y, Miki Y, Suzuki T, Takagi K,
Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N and
Sasano H: Runx2 in human breast carcinoma: Its potential roles in
cancer progression. Cancer Sci. 101:2670–2675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Underwood KF, D'Souza DR, Mochin-Peters M,
Pierce AD, Kommineni S, Choe M, Bennett J, Gnatt A, Habtemariam B,
MacKerell AD Jr and Passaniti A: Regulation of RUNX2 transcription
factor-DNA interactions and cell proliferation by vitamin D3
(cholecalciferol) prohormone activity. J Bone Miner Res.
27:913–925. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Kim MS, Gernapudi R, Choi EY, Lapidus RG
and Passaniti A: Characterization of CADD522, a small molecule that
inhibits RUNX2-DNA binding and exhibits antitumor activity.
Oncotarget. 8:70916–70940. 2017.PubMed/NCBI
|
|
139
|
Tandon M, Gokul K, Ali SA, Chen Z, Lian J,
Stein GS and Pratap J: Runx2 mediates epigenetic silencing of the
bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells.
Mol Cancer. 11:272012. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Lotem J, Levanon D, Negreanu V, Bauer O,
Hantisteanu S, Dicken J and Groner Y: Runx3 at the interface of
immunity, inflammation and cancer. Biochim Biophys Acta.
1855:131–143. 2015.PubMed/NCBI
|
|
141
|
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada
K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al: RUNX3, a
novel tumor suppressor, is frequently inactivated in gastric cancer
by protein mislocalization. Cancer Res. 65:7743–7750. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Goh YM, Cinghu S, Hong ET, Lee YS, Kim JH,
Jang JW, Li YH, Chi XZ, Lee KS, Wee H, et al: Src kinase
phosphorylates RUNX3 at tyrosine residues and localizes the protein
in the cytoplasm. J Biol Chem. 285:10122–10129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito
K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, et al: RUNX3 is
frequently inactivated by dual mechanisms of protein
mislocalization and promoter hypermethylation in breast cancer.
Cancer Res. 66:6512–6520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Chen LF: Tumor suppressor function of
RUNX3 in breast cancer. J Cell Biochem. 113:1470–1477.
2012.PubMed/NCBI
|
|
145
|
Li QL, Ito K, Sakakura C, Fukamachi H,
Inoue KI, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al: Causal
relationship between the loss of RUNX3 expression and gastric
cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Fujii S, Ito K, Ito Y and Ochiai A:
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by
increasing histone H3 methylation. J Biol Chem. 283:17324–17332.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Tsang YH Lamb A and Chen LF: New insights
into the inactivation of gastric tumor suppressor RUNX3: The role
of H. pylori infection. J Cell Biochem. 112:381–386. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Katayama Y, Takahashi M and Kuwayama H:
Helicobacter pylori causes runx3 gene methylation and its loss of
expression in gastric epithelial cells, which is mediated by nitric
oxide produced by macrophages. Biochem Biophys Res Commun.
388:496–500. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yong WP; National University Hospital,
Singapore, : The effect of preoperative docetaxel, cisplatin and
capecitabine on serum RUNX3 hypermethylation status in patients
with gastric and lower oesophagus adenocarcinoma. Clin Trials.
12017.
|
|
150
|
Hor YT, Voon DC, Koo JK, Wang H, Lau WM,
Ashktorab H, Chan SL and Ito Y: A role for RUNX3 in
inflammation-induced expression of IL23A in gastric epithelial
cells. Cell Rep. 8:50–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
National Institutes of Health: GDC data
portal: TCGA-HNSC project. US Dep Heal Hum Serv|Natl Institutes
Heal. 12018.
|
|
152
|
Bae SC, Kolinjivadi AM and Ito Y:
Functional relationship between p53 and RUNX proteins. J Mol Cell
Biol. Dec 11–2018.(Epub ahead of print). doi: 10.1093/jmcb/mjy076.
PubMed/NCBI
|
|
153
|
Lee JW, van Wijnen A and Bae SC: RUNX3 and
p53: How two tumor suppressors cooperate against oncogenic ras? Adv
Exp Med Biol. 962:321–332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Saha A and Robertson ES: Epstein-barr
virus-associated B-cell lymphomas: Pathogenesis and clinical
outcomes. Clin Cancer Res. 17:3056–3063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Gunnell A, Webb HM, Wood CD, McClellan MJ,
Wichaidit B, Kempkes B, Jenner RG, Osborne C, Farrell PJ and West
MJ: RUNX super-enhancer control through the Notch pathway by
Epstein-Barr virus transcription factors regulates B cell growth.
Nucleic Acids Res. 44:4636–4650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Spender LC, Cornish GH, Sullivan A and
Farrell PJ: Expression of transcription factor AML-2 (RUNX3,
CBF(alpha)-3) Is Induced by Epstein-Barr Virus EBNA-2 and
correlates with the B-cell activation phenotype. J Virol.
76:4919–4927. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Levanon D, Bernstein Y, Negreanu V, Bone
KR, Pozner A, Eilam R, Lotem J, Brenner O and Groner Y: Absence of
Runx3 expression in normal gastrointestinal epithelium calls into
question its tumour suppressor function. EMBO Mol Med. 3:593–604.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Lotem J, Levanon D, Negreanu V and Groner
Y: The false paradigm of RUNX3 function as tumor suppressor in
gastric cancer. J Cancer Ther. 4:16–25. 2013. View Article : Google Scholar
|
|
159
|
Levanon D, Negreanu V, Lotem J, Bone KR,
Brenner O, Leshkowitz D and Groner Y: Transcription Factor Runx3
regulates interleukin-15-dependent natural killer cell activation.
Mol Cell Biol. 34:1158–1169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Whittle MC, Izeradjene K, Rani PG, Feng L,
Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE,
et al: RUNX3 controls a metastatic switch in pancreatic ductal
adenocarcinoma. Cell. 161:1345–1360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Whittle MC and Hingorani SR: RUNX3 defines
disease behavior in pancreatic ductal adenocarcinoma. Mol Cell
Oncol. 3:e10765882015. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Jian Z, Cheng T, Zhang Z, Raulefs S, Shi
K, Steiger K, Maeritz N, Kleigrewe K, Hofmann T, Benitz S, et al:
Glycemic variability promotes both local invasion and metastatic
colonization by pancreatic ductal adenocarcinoma. Cell Mol
Gastroenterol Hepatol. 6:429–449. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Lotem J, Levanon D, Negreanu V, Bauer O,
Hantisteanu S, Dicken J and Groner Y: Runx3 in immunity,
inflammation and cancer. Adv Exp Med Biol. 962:369–393. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Berger AH, Knudson AG and Pandolfi PP: A
continuum model for tumour suppression. Nature. 476:163–169. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Tsunematsu T, Kudo Y, Iizuka S, Ogawa I,
Fujita T, Kurihara H, Abiko Y and Takata T: RUNX3 has an oncogenic
role in head and neck cancer. PLoS One. 4:e58922009. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Manandhar S and Lee YM: Emerging role of
RUNX3 in the regulation of tumor microenvironment. BMB Rep.
51:174–181. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Pattabiraman DR and Weinberg RA: Tackling
the cancer stem cells-what challenges do they pose? Nat Rev Drug
Discov. 13:497–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Gopal S, Saraswati S, Sanyal M, Bulbule A,
Ramdasi A, Kumar D, Behera R, Ahmed M, Chakraborty G, Kumar V, et
al: Therapeutic targeting of osteopontin in breast cancer cells.
In: Breast cancer-current and alternative therapeutic modalities.
InTech. 23–36. 2011.
|
|
169
|
Osorio KM, Lilja KC and Tumbar T: Runx1
modulates adult hair follicle stem cell emergence and maintenance
from distinct embryonic skin compartments. J Cell Biol.
193:235–250. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Fortini ME: Notch Signaling: The core
pathway and its posttranslational regulation. Dev Cell. 16:633–647.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S,
Chen Y and Wu K: Notch signaling and EMT in non-small cell lung
cancer: Biological significance and therapeutic application. J
Hematol Oncol. 7:872014. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Thouverey C and Caverzasio J: Focus on the
p38 MAPK signaling pathway in bone development and maintenance.
Bonekey Rep. 4:7112015. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Franceschi RT, Xiao G, Jiang D,
Gopalakrishnan R, Yang S and Reith E: Multiple signaling pathways
converge on the Cbfa1/Runx2 transcription factor to regulate
osteoblast differentiation. Connect Tissue Res. 44 (Suppl
1):S109–S116. 2003. View Article : Google Scholar
|
|
174
|
Nikitovic D, Kavasi RM, Berdiaki A,
Papachristou DJ, Tsiaoussis J, Spandidos DA, Tsatsakis AM and
Tzanakakis GN: Parathyroid hormone/parathyroid hormone-related
peptide regulate osteosarcoma cell functions: Focus on the
extracellular matrix (Review). Oncol Rep. 36:1787–1792. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Cohen-Solal KA, Boregowda RK and Lasfar A:
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving
force for tumor progression. Mol Cancer. 14:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Petcherski AG and Kimble J: Mastermind is
a putative activator for Notch. Curr Biol. 10:R471–R473. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Nakagawa M, Ichikawa M, Kumano K, Goyama
S, Kawazu M, Asai T, Ogawa S, Kurokawa M and Chiba S: AML1/Runx1
rescues Notch1-null mutation-induced deficiency of para-aortic
splanchnopleural hematopoiesis. Blood. 108:3329–3334. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Burns CE, Traver D, Mayhall E, Shepard JL
and Zon LI: Hematopoietic stem cell fate is established by the
Notch-Runx pathway. Genes Dev. 19:2331–2342. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Meier-Stiegen F, Schwanbeck R, Bernoth K,
Martini S, Hieronymus T, Ruau D, Zenke M and Just U: Activated
Notch1 target genes during embryonic cell differentiation depend on
the cellular context and include lineage determinants and
inhibitors. PLoS One. 5:e114812010. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Ann EJ, Kim HY, Choi YH, Kim MY, Mo JS,
Jung J, Yoon JH, Kim SM, Moon JS, Seo MS, et al: Inhibition of
Notch1 signaling by Runx2 during osteoblast differentiation. J Bone
Miner Res. 26:317–330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Shen Q and Christakos S: The vitamin D
receptor, Runx2, and the notch signaling pathway cooperate in the
transcriptional regulation of osteopontin. J Biol Chem.
280:40589–40598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Fu YX, Chang AC, Fournier M, Chang L,
Niessen K and Karsan A: RUNX3 maintains the mesenchymal phenotype
after termination of the notch signal. J Biol Chem.
286:11803–11813. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Cadigan KM and Peifer M: Wnt signaling
from development to disease: Insights from model systems. Cold
Spring Harb Perspect Biol. 1:a0028812009. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Chen F, Liu X, Bai J, Pei D and Zheng J:
The emerging role of RUNX3 in cancer metastasis (Review). Oncol
Rep. 35:1227–1236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Medina MA, Ugarte GD, Vargas MF, Avila ME,
Necuñir D, Elorza AA, Gutiérrez SE and De Ferrari GV: Alternative
RUNX1 promoter regulation by Wnt/β-catenin signaling in leukemia
cells and human hematopoietic progenitors. J Cell Physiol.
231:1460–1467. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Moore A, Tahinci E, Lee E and Hiebert S:
RUNX1-ETO stimulates wnt signaling by inhibiting the function of
ETO family member proteins. Blood. 104:25542004.
|
|
187
|
Dong YF, Soung do Y, Schwarz EM, O'Keefe
RJ and Drissi H: Wnt induction of chondrocyte hypertrophy through
the Runx2 transcription factor. J Cell Physiol. 208:77–86. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Gaur T, Lengner CJ, Hovhannisyan H, Bhat
RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS
and Lian JB: Canonical WNT signaling promotes osteogenesis by
directly stimulating Runx2 gene expression. J Biol Chem.
280:33132–33140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Attisano L and Labbé E: TGFbeta and Wnt
pathway cross-talk. Cancer Metastasis Rev. 23:53–61. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Ju X, Ishikawa TO, Naka K, Ito K, Ito Y
and Oshima M: Context-dependent activation of Wnt signaling by
tumor suppressor RUNX3 in gastric cancer cells. Cancer Sci.
105:418–424. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Chimge NO and Frenkel B: The RUNX family
in breast cancer: Relationships with estrogen signaling. Oncogene.
32:2121–2130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Mitsuda Y, Morita K, Kashiwazaki G,
Taniguchi J, Bando T, Obara M, Hirata M, Kataoka TR, Muto M, Kaneda
Y, et al: RUNX1 positively regulates ErbB2/HER2 signaling pathway
through modulating the expression of SOS1 in gastric cancer cells.
Sci Rep. 8:64232018. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Khalid O, Baniwal SK, Purcell DJ, Leclerc
N, Gabet Y, Stallcup MR, Coetzee GA and Frenkel B: Modulation of
Runx2 activity by estrogen receptor-alpha: Implications for
osteoporosis and breast cancer. Endocrinology. 149:5984–5995. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Chimge NO, Baniwal SK, Little GH, Chen YB,
Kahn M, Tripathy D, Borok Z and Frenkel B: Regulation of breast
cancer metastasis by Runx2 and estrogen signaling: The role of
SNAI2. Breast Cancer Res. 13:R1272011. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Teplyuk NM, Galindo M, Teplyuk VI, Pratap
J, Young DW, Lapointe D, Javed A, Stein JL, Lian JB, Stein GS and
van Wijnen AJ: Runx2 regulates G protein-coupled signaling pathways
to control growth of osteoblast progenitors. J Biol Chem.
283:27585–27597. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Berry NB, Fan M and Nephew KP: Estrogen
Receptor-alpha Hinge-Region Lysines 302 and 303 regulate receptor
degradation by the proteasome. Mol Endocrinol. 22:1535–1551. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Subramanian K, Jia D, Kapoor-Vazirani P,
Powell DR, Collins RE, Sharma D, Peng J, Cheng X and Vertino PM:
Regulation of estrogen receptor alpha by the SET7 lysine
methyltransferase. Mol Cell. 30:336–347. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Fan M, Park A and Nephew KP: CHIP
(Carboxyl Terminus of Hsc70-Interacting Protein) promotes basal and
geldanamycin-induced degradation of estrogen receptor-alpha. Mol
Endocrinol. 19:2901–2914. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Duong V, Boulle N, Daujat S, Chauvet J,
Bonnet S, Neel H and Cavaillès V: Differential regulation of
estrogen receptor alpha turnover and transactivation by Mdm2 and
stress-inducing agents. Cancer Res. 67:5513–5521. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Huang B, Qu Z, Ong CW, Tsang YH, Xiao G,
Shapiro D, Salto-Tellez M, Ito K, Ito Y and Chen LF: RUNX3 acts as
a tumor suppressor in breast cancer by targeting estrogen receptor
α. Oncogene. 31:527–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Yano T, Ito K, Fukamachi H, Chi XZ, Wee
HJ, Inoue K, Ida H, Bouillet P, Strasser A, Bae SC and Ito Y: The
RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells
undergoing transforming growth factor beta-induced apoptosis. Mol
Cell Biol. 26:4474–4488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Krishnan V, Chong YL, Tan TZ, Kulkarni M,
Bin Rahmat MB, Tay LS, Sankar H, Jokhun DS, Ganesan A, Chuang LSH,
et al: TGFβ promotes genomic instability after loss of RUNX3.
Cancer Res. 78:88–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Chi XZ, Yang JO, Lee KY, Ito K, Sakakura
C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, et al: RUNX3 suppresses
gastric epithelial cell growth by inducing p21(WAF1/Cip1)
expression in cooperation with transforming growth factor
{beta}-activated SMAD. Mol Cell Biol. 25:8097–8107. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Ito K, Lim AC, Salto-Tellez M, Motoda L,
Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, et al: RUNX3
Attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
Cancer Cell. 14:226–237. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Tanaka S, Shiraha H, Nakanishi Y, Nishina
S, Matsubara M, Horiguchi S, Takaoka N, Iwamuro M, Kataoka J,
Kuwaki K, et al: Runt-related transcription factor 3 reverses
epithelial-mesenchymal transition in hepatocellular carcinoma. Int
J Cancer. 131:2537–2546. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Voon DC, Wang H, Koo JK, Nguyen TA, Hor
YT, Chu YS, Ito K, Fukamachi H, Chan SL, Thiery JP and Ito Y: Runx3
protects gastric epithelial cells against epithelial-mesenchymal
transition-induced cellular plasticity and tumorigenicity. Stem
Cells. 30:2088–2099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH,
Li YH, Kim MK, Kim DM, Choi BS, Kim EG, et al: Runx3 Inactivation
is a crucial early event in the development of lung adenocarcinoma.
Cancer Cell. 24:603–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Kilbey A, Blyth K, Wotton S, Terry A,
Jenkins A, Bell M, Hanlon L, Cameron ER and Neil JC: Runx2
disruption promotes immortalization and confers resistance to
oncogene-induced senescence in primary murine fibroblasts. Cancer
Res. 67:11263–11271. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Cameron ER, Blyth K, Hanlon L, Kilbey A,
Mackay N, Stewart M, Terry A, Vaillant F, Wotton S and Neil JC: The
Runx genes as dominant oncogenes. Blood Cells Mol Dis. 30:194–200.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Aronson BD, Fisher AL, Blechman K, Caudy M
and Gergen JP: Groucho-dependent and -independent repression
activities of Runt domain proteins. Mol Cell Biol. 17:5581–5587.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Fukushima-Nakase Y, Naoe Y, Taniuchi I,
Hosoi H, Sugimoto T and Okuda T: Shared and distinct roles mediated
through C-terminal subdomains of acute myeloid
leukemia/runt-related transcription factor molecules in murine
development. Blood. 105:4298–4307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Goyama S, Yamaguchi Y, Imai Y, Kawazu M,
Nakagawa M, Asai T, Kumano K, Mitani K, Ogawa S, Chiba S, et al:
The transcriptionally active form of AML1 is required for
hematopoietic rescue of the AML1-deficient embryonic para-aortic
splanchnopleural (P-Sp) region. Blood. 104:3558–3564. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Javed A, Barnes GL, Jasanya BO, Stein JL,
Gerstenfeld L, Lian JB and Stein GS: Runt homology domain
transcription factors (Runx, Cbfa, and AML) mediate repression of
the bone sialoprotein promoter: Evidence for promoter
context-dependent activity of Cbfa proteins. Mol Cell Biol.
21:2891–2905. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Neil JC, Gilroy K, Borlan G, Hay J, Terry
A and Kilbey A: The RUNX genes as conditional oncogenes: Insights
from retroviral targeting and mouse models. Adv Exp Med Biol.
962:247–264. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Miething C, Grundler R, Mugler C, Brero S,
Hoepfl J, Geigl J, Speicher MR, Ottmann O, Peschel C and Duyster J:
Retroviral insertional mutagenesis identifies RUNX genes involved
in chronic myeloid leukemia disease persistence under imatinib
treatment. Proc Natl Acad Sci USA. 104:4594–4599. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Burillo-Sanz S, Vargas MT, Morales-Camacho
RM, Caballero-Velázquez T, Sánchez J, García-Lozano JR, Pérez de
Soto I, Prats-Martín C, Bernal R and Pérez-Simón JA: RUNX1
amplification in AML with myelodysplasia-related changes and ring
21 chromosomes. Hematol Oncol. 35:894–899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Ito Y: Oncogenic potential of the RUNX
gene family: ‘Overview.’. Oncogene. 23:4198–4208. 2004. View Article : Google Scholar : PubMed/NCBI
|
